Furthermore, recent failures of drug targets in IBD, such as IL-17, IL-13, interferon (IFN)-γ, and chemokine receptor (CCR)-9, have indicated that single target therapy for IBD is difficult owing to pathogenic heterogeneity [4]. The gene discussed is IL17A; the disease is inflammatory bowel disease.